Skip to content
Friday 28 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,824.26
+0.29%
DAX
26,569.99
+0.77%
CAC 40
8,401.18
+0.98%
STOXX 50
6,485.67
+0.95%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Thursday 23 February 2017 9:34 am

This is how City analysts reacted to RSA’s bumper results

By: Oliver Gill

Add as a preferred source on Google

RSA was pretty chipper this morning about its annual results.

Beating consensus expectations, the FTSE 100's share price was one of the index leaders on what was otherwise subdued early trading – it was up over five per cent minutes after the open.

RSA 2016 results (£m unless stated)

Expectation

Actual

Net written premiums 6,337 6,408
Underwriting result 361 380
Investment result 282 298
Operating result 626 655
Combined ratio 94.2% 93.8%
Earnings per share 36.4p 39.5p
Dividend per share 15.1p 16.0p

Read more: RSA smashes expectations as chief exec Hester says turnaround is complete

On the face of it the market reaction was made sense.

But while RSA boss chief executive Stephen Hester warned of future "banana skins" on a conference call this morning, some City analysts have not got quite so carried away. Here are two of their key concerns.

[stockChart code="RSA" date="2017-02-23 09:25"]

Value baked in?

If you'd bought shares in RSA a year ago, you'd be a pretty happy bunny right now. Trading around 40 per cent higher than 12 months ago, they are also a considerable premium to the reported value Zurich ascribed to the firm in 2015.

Zurich abandoned its 550p per share takeover attempt in September. This morning the owner of More Than was trading at over 600p per share.

But, Barrie Cornes, an analyst at Panmure Gordon exercised caution about this morning's further jump. He said:

We like what Stephen Hester is doing at RSA… but, in our view, this good news is now all in the share price.

The sentiment was shared by Eamonn Flanagan of Shore Capital. We said that "despite the positive noises… we view the shares as significantly overvalued".

Read more: Stephen Hester sees positives from Brexit vote for RSA

Both Flanagan and Cornes warned RSA's shares were trading a over two times the value of the firm's net tangible assets.

Solvency

RSA said its Solvency II ratio – the proportion of capital it has set aside to underwriting, investment and operational risks – had increased year-on-year, from 143 per cent to 158 per cent. 

Flanagan stressed this was at the top end of its targeted range of between 130 per cent and 160 per cent.

However, the sale of its UK legacy liabilities to Enstar – announced a few weeks ago – is likely to improve the ratio considerably by 17 to 20 per cent. 

 

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Trending Articles

  • Pensioners to hand over bank statements in government benefits crackdown

  • Jamie Carragher: HMRC petitions for Sky Sports star to be declared bankrupt

  • Brewdog founder James Watt hits out at ‘total silence’ over new venture

  • Lloyds Bank and Halifax users unable to use app in latest outage

  • Economists urge Bank of England to halt bond sales as borrowing costs climb

More from Morning Wire

  • IFF Reports Second Quarter 2026 Results; Announces Use of Proceeds Plan for Food Ingredients Divestiture

    Business Wire
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
  • Algoma Central Corporation Reports Financial Results for the 2026 Second Quarter

    Business Wire
  • WP Engine Opens Smart Search AI to the WordPress Ecosystem

    Business Wire
  • Moody’s Brings Its Decision-Grade Intelligence to Gemini Enterprise for Financial Services

    Business Wire
  • IGI Reports Second Quarter and First Six Months of 2026 Unaudited Financial Results and Declares Ordinary Common Share Dividend

    Business Wire
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook